-
-
-
-
-
-
-
FDA accepts Jazz Pharmaceuticals filing for cancer drug combination
-
-
-
-
-
-
-
Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)
-
-
-
-
-
-
-
Jazz Pharmaceuticals (JAZZ) PT Lowered to $174 at RBC Capital
-
-
-
-
-
-
-
Ligand Reports First Quarter 2024 Financial Results
-
-
-
-
-
-
-
Jazz Pharmaceuticals (JAZZ) Tops Q1 EPS by 21c
-
-
-
-
-
-
-
Jazz Pharmaceuticals (JAZZ) Provides COVID-19 Business Update
-
15,672 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

